Navigation Links
Study defines effective microbicide design for HIV/AIDS prevention

Duke University biomedical engineers have developed a computer tool they say could lead to improvements in topical microbicides being developed for women to use to prevent infection by the virus that causes AIDS.

Providing women with improved microbicides is a pressing challenge because women now account for a growing number of new infections worldwide, the researchers said.

By applying fundamentals of physics and chemistry, the researchers developed a computer model that can predict the effectiveness of various microbicidal recipes in destroying human immunodeficiency virus (HIV) before it reaches vulnerable body tissues.

Using the tool, the researchers have determined that a thin, long-lasting coating of microbicide delivered to susceptible tissues in a woman's vagina can significantly reduce the spread of HIV.

The researchers reported their findings in the September 2006 Biophysical Journal.

The findings emphasize a critical role for the "delivery vehicle," the various polymer gels or creams that carry the active antimicrobial ingredients, in determining the success or failure of microbicides, according to the researchers. Yet, they add, most scientists have concentrated on improving the antimicrobial compounds themselves, rather than their delivery.

"There is a huge push to produce microbicides that would have any effectiveness at all in reducing the spread of HIV, particularly in places like Africa and Southeast Asia where the disease is rampant," said David Katz, a professor of biomedical engineering at Duke's Pratt School of Engineering and one of the computer tool's developers. "We are developing methodologies to make the next round of microbicides even better."

"Existing microbicides are excellent in terms of their ability to inactivate HIV," added Anthony Geonnotti, the study's lead investigator, who is a Ph.D. candidate in Katz's laboratory. "Improvements to future generations of microbicides
'"/>

Source:Duke University


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
(Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... , April 27, 2015  For more than ... trade show has been the premier worldwide event for ... 2015 is a must-attend event for any local, national, ... into the emerging commercial markets and current applications of ... innovations of this projected $48 billion industry, and how ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... binds to bile in the small intestine may hold the ... conditions such as obstructive jaundice or irritable bowel syndrome, researchers ... we've identified is one of the mechanisms for how the ... intestine, and how it prevents them from getting into other ...
... genetic mutation that protects against HIV increases the risk of ... study appearing online on January 9th in The Journal of ... deletion in a gene that encodes a protein called CCR5, ... HIV to infect cells. Individuals with two copies of ...
... at UT Southwestern Medical Center shows that on a ... work similarly to the way in which certain hormones ... eradicate worm infections that afflict a third of the ... molecule that activates genes involved in the development and ...
Cached Biology News:Gut protein found to protect against infection and intestinal breakdown 2Genetic mutation linked to West Nile virus infection 2Worm hormone discovery may aid fight against parasitic disease 2Worm hormone discovery may aid fight against parasitic disease 3
(Date:5/21/2015)... May 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... company that develops and commercializes proprietary technologies and products ... operational results for the second fiscal quarter ended March ... Company continued to advance business with our existing customers ... , President and CEO of SQI. "The delivery of ...
(Date:5/21/2015)... May 21, 2015  Prima Biomed Ltd. (NASDAQ: ... striving to become a leader in the development of ... that the final CVac data from the Phase II ... trend for a clinically meaningful improvement in Overall Survival ... patients. In the group of second remission ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Correction Continues after Big Move - BrokerBank Securities, Inc. 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Global Survey on Flow Cytometry Adoption Trends 2015 2
... Pharmaceuticals,a division of Wyeth (NYSE: WYE ), ... (FDA) has approved PRISTIQ(TM) (desvenlafaxine), a,structurally novel, once-daily ... major depressive disorder (MDD). Wyeth,expects to begin shipping ... 2008., "We are pleased to be able ...
... BETHESDA, Md., Feb. 29 Micromet, Inc.,(Nasdaq: ... for the treatment of cancer, inflammation and autoimmune,diseases, ... Chief,Executive Officer of Micromet, will present at the ... March 4,2008, at 10:30 am ET at the ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ... focused on,endocrine therapy and oncology, today announced ... Senior Vice President, Administrative & Legal,Affairs and ... position of,Vice President and Chief Financial Officer ...
Cached Biology Technology:FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 2FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 4FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 5FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 6FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 7FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 8FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 9Micromet to Present at the Susquehanna Financial Group's SIGnificant Investment Options Conference on March 4, 2008 2AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs 2
solute carrier family 25, member 13 (citrin)...
poliovirus receptor-related 2 (herpesvirus entry mediator B), mRNA...
CREB-2 (H-290)...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Biology Products: